What is the Origin of Incretin System Targeting?

The term originates in endocrinology and gastroenterology, following the discovery and characterization of incretin hormones in the latter half of the 20th century. "Targeting" refers to the development of pharmacological agents, such as GLP-1 receptor agonists, that mimic or potentiate the effects of these endogenous gut hormones. The clinical application is rooted in addressing the pathophysiology of type 2 diabetes and obesity.

What is the Mechanism of Incretin System Targeting?

Upon food intake, incretin hormones are secreted by enteroendocrine cells into the bloodstream, where they travel to the pancreas to enhance insulin release specifically when blood glucose levels are high. GLP-1 also acts on the brain to reduce appetite and on the stomach to delay emptying. Therapeutic targeting involves using synthetic analogs that resist rapid enzymatic degradation by DPP-4, thereby prolonging the beneficial effects on glucose homeostasis and energy balance regulation.

Incretin System Targeting ∞ Area

Incretin System Targeting

Meaning

A therapeutic strategy focused on modulating the activity of the incretin hormones, primarily Glucagon-like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP), which are released from the gut in response to nutrient ingestion. Targeting this system aims to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety. This approach is a cornerstone in the clinical management of metabolic health and weight regulation.